During SOHO 2019, Houston, US, the Lymphoma Hub asked Dr Owen A. O’Connor from Columbia University, New York, US, about treatments in the pipeline for T-cell lymphoma. He gives an update on the recent clinical developments for patients with relapsed or refractory diseases. He also describes treatment paradigms incorporating combinations of drugs with novel backbones, which hopefully in the future will replace CHOP-based therapies.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
SOHO 2019 | What is in the pipeline for the treatment of T-cell lymphoma?
What is in the pipeline for the treatment of T-cell lymphoma?
More about...
Adult T-cell leukemia/lymphoma
Anaplastic large cell lymphoma, ALK-negative
Anaplastic large cell lymphoma, ALK-positive
Angioimmunoblastic T-cell lymphoma
Brentuximab vedotin
CHOP
Elina Simanovits
Epstein-Barr virus-positive T-cell lymphoma
Joanna Nikitorowicz-Buniak
Mature T and NK cell neoplasms
Mycosis fungoides
Owen O'Connor
Pembrolizumab
Peripheral T-cell lymphoma
Pralatrexate
Romidepsin
SOHO 2019
Sézary syndrome
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month